Welcome, fellow investors! Today, we’re taking a deep dive into Hims & Hers Health, Inc. (HIMS), a dynamic player with a $7.90 billion market cap in the Drug Manufacturers – Specialty & Generic industry. As an expert financial journalist, I understand you’re looking for clear, actionable insights, not just numbers. The big question on everyone’s mind is whether HIMS’s current stock price truly reflects its intrinsic value and if it’s positioned for robust future growth.
Navigating the market can be tricky, and deciding whether to invest in a company like Hims & Hers Health, Inc. requires a nuanced perspective. We’re here to unravel the complexities, providing you with a comprehensive analysis so you can make an informed decision. Let’s explore how HIMS stock is performing in the current market landscape.
HIMS Stock: Key Insights You Need to Know Today
As of November 2025, HIMS is trading at $34.71, and it’s currently showing signs of a bearish trend. The stock is holding below both its 50-day and 200-day moving averages, which is a key indicator for many traders. However, it’s not all gloom and doom; analysts are quite optimistic, projecting a 1-year price target of $46.00, which suggests a potential +74.5% upside from today’s price.
Here’s the thing: this stock comes with a significant amount of volatility, measured at 43.4% annualized. This means you can expect wide price swings, which can be both an opportunity and a risk. Fundamentally, Hims & Hers Health, Inc. presents a mixed bag. They’ve demonstrated solid revenue growth, up 49.20% year-over-year, which is impressive. Yet, they’ve also experienced a contraction in earnings, down -80.30% year-over-year, which definitely warrants closer examination.
What This HIMS Stock Report Covers
We’re committed to giving you a clear, jargon-free breakdown of HIMS stock, helping you build a solid investment thesis. Our goal is to empower you with the knowledge to make smart decisions, whether you’re a long-term investor or chasing short-term gains.
Here’s what we’ll cover:
- Is now a good time to buy HIMS? Technically, the sentiment is “Bearish,” but the Relative Strength Index (RSI) is signaling oversold conditions at 23.1. Fundamentally, we’ll need to be cautious, especially considering debt levels and recent growth metrics.
- Can HIMS’s core operations drive future growth? The company’s future success will largely hinge on its performance within the Drug Manufacturers – Specialty & Generic sector and its ability to effectively navigate competitive pressures.
- What are the biggest risks for HIMS investors? Hims & Hers Health carries a substantial debt load of $1.12 billion. This could become a significant headwind, particularly in a high-interest-rate environment. Plus, competition is fierce, coming from both established industry giants and innovative newcomers.
Many stock analyses either bombard you with confusing jargon or oversimplify complex situations. That’s not our style. We’re here to provide clear, actionable information that benefits you, regardless of your investment horizon. So, is Hims & Hers Health, Inc. the right investment to help your money grow? Or are there underlying issues to be wary of? Stick with us as we dive into the details.
HIMS Stock Performance: Key Metrics & Forecast Summary
Let’s kick things off with a snapshot of HIMS’s current standing and what the models are suggesting for its future.
| Metric | Value | Notes |
|---|---|---|
| Current Price | $34.71 | Live Market Price |
Price Targets & Forecasts for HIMS
| Forecast Type | Price | Potential Change |
|---|---|---|
| 1-Month Forecast | $34.71 | -0.0% |
| 1-Year Forecast | $60.56 | +74.5% |
| Analyst Mean Target | $46.00 | +32.5% |
Trend & Momentum Indicators for HIMS
| Indicator | Value | Interpretation |
|---|---|---|
| Trend | Bearish | Price < SMA 50/200 |
| RSI (14-day) | 23.1 | Oversold ❄️ |
| MACD | -0.10 | Bearish Short-Term Trend |
Key Technical Levels for HIMS Stock
| Level | Value |
|---|---|
| Above SMA 50 | ❌ $46.65 |
| Above SMA 200 | ❌ $51.34 |
| 52-Week Range | $23.97 – $72.98 |
Volatility & Sensitivity for HIMS
| Metric | Value | Interpretation |
|---|---|---|
| Volatility (30d Ann.) | 43.4% | 🌪️ |
| Beta (vs. Market) | 2.40x | 🎢 High Sensitivity |
| Green Days (30d) | 12/30 (40%) | 🟡 |
HIMS Ownership & Short Interest
| Metric | Value | Interpretation |
|---|---|---|
| Institutional Ownership | 94.27% | 🏛️ |
| Short % of Float | 38.12% | 😰 High Bearish Bets |
Right now, HIMS stock is trading at $34.71. From a technical perspective, it’s showing a bearish pattern because its price sits below both the 50-day moving average (at $46.65) and the 200-day moving average (at $51.34). This suggests that the stock has been losing momentum recently.
However, there’s an interesting counterpoint: the Relative Strength Index (RSI) is at 23.1, which indicates oversold conditions. While the MACD indicator points to a bearish short-term trend, this oversold RSI could hint at a potential bounce or a minor pullback before an upward move.
Looking back over the past year, HIMS has traded within a wide range, from $23.97 to $72.98. This wide 52-week range tells us two things: first, the stock has experienced significant pullbacks from its highs. Second, the current price is closer to the lower end of that range, which might imply that extreme swings are less likely unless major news breaks.
Analysts are forecasting substantial growth, with a 1-year target of $60.56 (+74.5%) and an average consensus target of $46.00 (+32.5%). What’s particularly noteworthy is the high institutional ownership at 94.27%. Yet, the high short interest, at 38.12% of the float, suggests a significant number of investors are betting against the stock, indicating high perceived risk. This is a dynamic tension worth watching.
HIMS Stock Price Forecast: Detailed Monthly Projections
Let’s dive into the detailed month-by-month forecast for HIMS, which projects an overall range of $34.71 to $82.30. This table breaks down the anticipated price bands, the potential Return on Investment (ROI) compared to the current price, and the model’s signal for each period.
Over the forecast horizon, from November 2025 to November 2026, the model projects HIMS’s price to fluctuate between approximately $34.71 and $82.30. What’s interesting is that the projected price range remains relatively consistent, moving from a tight band of $34.71 – $34.71 to a slightly wider one of $55.81 – $66.65. This implies a fairly stable level of forecast uncertainty throughout the period.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($34.71) | Model Signal |
|---|---|---|---|---|---|
| 2025-11 | $34.71 | $34.71 | $34.71 | -0.0% | Hold/Neutral |
| 2025-12 | $39.69 | $45.70 | $50.60 | 31.7% | Consider Buy |
| 2026-01 | $41.31 | $45.82 | $50.51 | 32.0% | Consider Buy |
| 2026-02 | $47.99 | $62.38 | $72.72 | 79.7% | Consider Buy |
| 2026-03 | $59.01 | $66.69 | $71.58 | 92.1% | Consider Buy |
| 2026-04 | $44.03 | $50.69 | $61.07 | 46.0% | Consider Buy |
| 2026-05 | $45.21 | $55.09 | $72.55 | 58.7% | Consider Buy |
| 2026-06 | $69.19 | $76.99 | $82.30 | 121.8% | Consider Buy |
| 2026-07 | $64.14 | $74.09 | $81.46 | 113.5% | Consider Buy |
| 2026-08 | $61.74 | $70.42 | $77.72 | 102.9% | Consider Buy |
| 2026-09 | $48.15 | $55.10 | $68.10 | 58.7% | Consider Buy |
| 2026-10 | $51.39 | $60.56 | $67.80 | 74.5% | Consider Buy |
| 2026-11 | $55.81 | $61.49 | $66.65 | 77.1% | Consider Buy |
It’s important to remember that these forecasts are model-based estimates. They are inherently uncertain and can change based on evolving data and market conditions. These projections do not guarantee future prices, so always conduct your own research.
Hims & Hers Health (HIMS) Company Profile & Business Overview
Let’s get to know the company behind the stock. Understanding Hims & Hers Health, Inc.’s business model and market position is crucial for any investor.
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers – Specialty & Generic |
| Market Cap | $7.90 B |
| Employees | 1,637 |
| Website | https://www.hims.com |
HIMS Business Overview: What Does Hims & Hers Health Do?
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers with licensed healthcare professionals. They serve customers not just in the United States but also across the United Kingdom and other international markets. This broad reach is a significant part of their growth strategy.
The company offers a diverse portfolio of curated prescription and non-prescription health and wellness products and services. These are conveniently available for purchase directly through their websites and mobile application. They provide recurring prescription medication services, along with ongoing care from healthcare providers.
Beyond prescriptions, HIMS also offers a variety of over-the-counter drugs, devices, cosmetics, and supplements. These products primarily focus on general wellness, sexual health, skincare, and hair care. For instance, their wellness specialty category includes products like melatonin and biotin. In skincare, you’ll find moisturizers, creams, sunscreens, and face oils. Sexual health offerings range from condoms to vibrators, while hair care includes shampoos, conditioners, and topical treatments like minoxidil.
What’s more, Hims & Hers Health provides medical consultation and post-consultation support services. They also distribute health and wellness products through various wholesale partners, expanding their market footprint. The company is also innovating with “Labs,” a service that measures key health markers over time and offers doctor-developed action plans. Hims & Hers Health, Inc. is headquartered in San Francisco, California.
HIMS Stock Valuation: Is Hims & Hers Health Overpriced?
When we talk about valuation, it’s about more than just market cap. It’s about understanding what investors are paying for and whether that price is justified. Hims & Hers Health, Inc. is certainly recognized as a significant player in its industry, boasting a $7.90 billion market cap.
However, its enterprise value (EV) tells an even more complete story, sitting higher at $8.39 billion. This difference is largely due to $490.00 million in debt that adds to the company’s total value. While investors seem confident about Hims & Hers Health, Inc.’s future earnings potential, it’s crucial to keep a close eye on that debt load.
The valuation ratios offer a compelling narrative. With an EV/Revenue of 3.79x and an EV/EBITDA of 49.79x, Hims & Hers Health, Inc. is trading at a premium compared to many of its peers. This premium often reflects the company’s strong market position and valuable brand assets. However, it also means there might be less room for error in its performance.
The upcoming earnings report on November 3, 2025, will be a critical moment. It will show whether Hims & Hers Health, Inc.’s businesses can truly grow into this elevated valuation. Essentially, you might be paying for quality with HIMS, but as we know, quality rarely comes cheap.
| Metric | Value |
|---|---|
| Market Cap | $7.90 B |
| Enterprise Value | $8.39 B |
| EV/Revenue (TTM) | 3.79x |
| EV/EBITDA (TTM) | 49.79x |
| Next Earnings Date | 2025-11-03 |
HIMS Share Statistics: Ownership, Float & Short Interest
Understanding who owns a company’s shares and how many are available for public trading can provide valuable insights into its stability and potential for price movements.
Approximately 5.9% of Hims & Hers Health, Inc.’s shares are closely held by insiders or strategic investors. This leaves about 206 million shares available for public trading, known as the float. Because the float is relatively high, investors can typically trade this stock without causing significant, sudden price shifts. However, it’s always wise to be aware that the company could issue more shares, which might dilute the value of existing stock.
Executives and major shareholders hold a significant stake, owning 6.29% of the company. This alignment of interests often provides a sense of confidence for other shareholders. Institutional ownership is also quite substantial, coming in at an impressive 94.27%. This high level of institutional backing suggests a degree of stability and confidence in the stock from large professional investors.
Now, let’s talk about short interest. Currently, about 70 million shares are shorted, which represents 38.12% of the float. This is a high percentage, suggesting that a significant portion of the market is betting against the stock, indicating a high perceived risk. Investors should closely watch changes in short interest, as a sharp increase could signal growing doubt among bearish investors. Conversely, very low short interest during positive news might sometimes discourage a “short squeeze.”
| Metric | Value |
|---|---|
| Shares Outstanding | 219 M |
| Implied Shares Outstanding | 228 M |
| Shares Float | 206 M |
| Insider Ownership | 6.29% |
| Institutional Ownership | 94.27% |
| Shares Short | 70 M |
| Short Ratio (Days To Cover) | 2.50x |
| Short % of Float | 38.12% |
| Shares Short (Prior Month) | 71 M |
| Short Date | 2025-10-31 |
HIMS Valuation Metrics: P/E, Price/Sales, EV/EBITDA Analysis
When evaluating HIMS, its valuation metrics offer a window into how the market currently perceives its worth. The company’s Trailing P/E ratio stands at 65.49x, and its Forward P/E is even higher at 75.46x. These figures clearly reflect a premium valuation, suggesting the market has stable earnings expectations. For investors, this warrants careful consideration; you’re paying a higher price for future earnings.
Meanwhile, HIMS’s Price/Sales ratio of 3.57x and Price/Book of 13.59x also indicate that the company trades at multiples that demand attention. These metrics are crucial for understanding the company’s market positioning relative to its revenue and book value.
From an enterprise value perspective, the EV/Revenue ratio of 3.79x suggests a reasonable valuation when looking at revenue. However, the EV/EBITDA multiple of 49.79x points to a potentially stretched valuation. Collectively, these metrics provide a comprehensive view of HIMS’s current market standing and highlight areas where its valuation might be considered elevated.
| Metric | Value |
|---|---|
| Trailing P/E | 65.49x |
| Forward P/E | 75.46x |
| Price/Sales (TTM) | $3.57 |
| Price/Book (MRQ) | $13.59 |
| EV/Revenue (TTM) | 3.79x |
| EV/EBITDA (TTM) | 49.79x |
HIMS Financial Health: Debt, Liquidity & Cash Flow Analysis
HIMS appears to be in robust financial health, exhibiting several key strengths that investors will appreciate. Its Return on Equity (ROE) of 26.21% and Return on Assets (ROA) of 5.56% are excellent indicators of highly efficient capital utilization, often seen in companies with strong growth trajectories.
However, the 1.92x Debt/Equity ratio, with $1.12 billion in total debt against $629.74 million in cash, reveals that HIMS has taken on a considerable amount of debt to fuel its operations and expansion. Despite this, the company’s ability to generate $325.08 million in operating cash flow (TTM) demonstrates that its core business can consistently produce cash, which is a significant underlying strength.
Looking at liquidity, the Current Ratio of 1.88x and Quick Ratio of 1.49x both signal a solid position, indicating that HIMS can comfortably cover its short-term liabilities. Furthermore, with $195.34 million in levered free cash flow, the company proves it can still generate substantial cash for shareholders even after meeting all its financial obligations.
| Metric | Value |
|---|---|
| Return on Equity (ROE TTM) | 26.21% |
| Return on Assets (ROA TTM) | 5.56% |
| Debt/Equity (MRQ) | 1.92x |
| Total Cash (MRQ) | $629.74 M |
| Total Debt (MRQ) | $1.12 B |
| Current Ratio (MRQ) | 1.88x |
| Quick Ratio (MRQ) | 1.49x |
| Operating Cash Flow (TTM) | $325.08 M |
| Levered Free Cash Flow (TTM) | $195.34 M |
HIMS Financial Efficiency: Asset Turnover & Cash Conversion Cycle
Hims & Hers Health demonstrates impressive financial efficiency, making the most of its assets to drive revenue. Its Asset Turnover of 3.12x means the company generates $3.12 in revenue for every dollar of assets it holds, indicating excellent utilization of its asset base.
The Inventory Turnover stands at 4.71x, showing that Hims & Hers Health sells and replaces its inventory roughly 4.7 times annually. This translates to about 77.5 Days Inventory Outstanding. Meanwhile, a Receivables Turnover of 363.64x and just 1.0 Days Sales Outstanding reflect incredibly efficient collections; customers are paying their bills very quickly. The Working Capital Turnover of 12.67x further highlights the highly efficient use of short-term assets to support sales, backed by a healthy Current Ratio of 1.88x, signaling robust liquidity.
The Cash Conversion Cycle, estimated at approximately ~78.5 days (partial), suggests it takes about 2.6 months for the company to convert its inventory and receivables into cash. This indicates a manageable cash conversion process. Finally, Hims & Hers Health’s Return on Invested Capital (ROIC) of 28.06% signifies strong capital efficiency, showcasing how effectively the company generates returns from the capital invested in its operations. Overall, Hims & Hers Health exhibits effective asset management that strongly supports its profitability. It’s always a good idea to compare these figures with industry peers to fully gauge its competitive standing.
| Metric | Value |
|---|---|
| Asset Turnover (TTM) | 3.12x |
| Inventory Turnover (TTM) | 4.71x |
| Receivables Turnover (TTM) | 363.64x |
| Working Capital Turnover (TTM) | 12.67x |
| Current Ratio (MRQ) | 1.88x |
| Days Sales Outstanding | 1.0 |
| Days Inventory Outstanding | 77.5 |
| Cash Conversion Cycle | ~78.5 days (partial) |
| Return on Invested Capital (ROIC TTM) | 28.06% |
HIMS Profitability & Growth: Margins, Revenue & Earnings Trends
A closer look at HIMS’s margin performance reveals that the company has a solid grip on its costs and pricing strategies. The impressive gross margin of 75.01% clearly shows their success in controlling production costs. Moreover, the 2.06% operating margin indicates healthy profits from their core operations, before accounting for interest and taxes.
An EBITDA margin of 7.62% suggests that HIMS is capable of generating strong cash flow from its operations. All things considered, HIMS has managed to retain approximately $6.050 in net profit for every dollar of revenue over the last twelve months. While the business is experiencing aggressive revenue growth at 49.20%, investors should closely monitor whether this pace can be sustained without eroding those crucial profit margins.
HIMS’s $168.50 million in EBITDA and $1.66 billion in gross profit demonstrate its raw earning power. The $133.79 million in net income then shows how effectively this power is translated into bottom-line results. It appears the company is skillfully balancing its pursuit of growth with the vital need to maintain profitability. Despite robust gross margins, there’s a noticeable gap between the company’s gross and net margins (75.01% vs. 6.05%). This discrepancy likely stems from higher operating expenses, interest costs, or taxes, which are key areas for investors to scrutinize. Moving forward, maintaining steady or improving margins will be paramount. HIMS will need to defend its pricing power and keep a tight rein on operating costs, especially if revenue growth begins to moderate.
| Metric | Value |
|---|---|
| Profit Margin (TTM) | 6.05% |
| Operating Margin (TTM) | 2.06% |
| Gross Margin (TTM) | 75.01% |
| EBITDA Margin (TTM) | 7.62% |
| Revenue (TTM) | $2.21 B |
| Quarterly Revenue Growth (YoY) | 49.20% |
| Gross Profit (TTM) | $1.66 B |
| EBITDA (TTM) | $168.50 M |
| Net Income (TTM) | $133.79 M |
| Earnings Growth (YoY) | -80.30% |
HIMS Dividends & Shareholder Returns: Is Hims & Hers Health Paying Out?
For many investors, dividends are a key consideration, offering a regular return on investment. Let’s see where HIMS stands on this front.
HIMS Dividend Policy: What Investors Need to Know
Based on the available data, HIMS does not currently pay a regular dividend. This decision often indicates that the company is prioritizing reinvesting its earnings back into the business. This strategy is common among growth-focused companies, aiming to fuel expansion and future appreciation rather than distributing profits directly to shareholders.
| Metric | Value |
|---|---|
| Payout Ratio | 0.00% |
| Trailing Dividend Yield | 0.00% |
HIMS Stock Technical Analysis: Trends, Momentum & Key Levels
Alright, let’s talk technicals. The current price for HIMS is $34.71, and the trend is definitely bearish, though it appears to be oversold. The stock has experienced downward pressure, losing -16.40% in the last 15 days alone. Is this a buying opportunity in disguise, or a warning of further declines? Let’s break down the key levels.
Trend Strength: HIMS Remains Bearish
HIMS is firmly entrenched in a bearish trend, trading below its key moving averages. This is a clear signal for caution among traders and investors.
What This Means for Traders?
The 20-day Simple Moving Average (SMA) at $39.19 is now acting as a significant overhead resistance level. As long as the price remains below this point, the bearish trend is likely to persist. A rejection from this average could easily lead to a re-test of recent lows, so keep a close eye on it.
Momentum Check: Is HIMS Stock Due for a Bounce?
The Relative Strength Index (RSI) is currently at 23.1, which indicates oversold conditions. This often hints at a potential bounce in the near future. However, simultaneously, the MACD histogram is negative, suggesting that any upward momentum might be starting to fade.
Trading Strategy:
This oversold RSI reading presents an interesting scenario. Aggressive traders might consider looking for a short-term buy signal, anticipating a rebound. Conservative traders, on the other hand, should wait for the RSI to confidently cross back above 30 to confirm a legitimate reversal before making a move.
Bollinger Bands: HIMS Stock Testing Critical Levels
The stock is currently trading near the middle of its Bollinger Bands, with the 20-day SMA at $39.19. The lower band, positioned at $32.26, offers the next crucial level of support. This setup suggests that the price is consolidating but still under pressure.
Volume Trends: Analyzing Conviction in HIMS Stock
Trading volume for HIMS is currently near its recent average. This provides a neutral confirmation of the current price action, neither strongly supporting nor contradicting the recent moves.
What’s the Concern?
Low volume rallies are inherently prone to sharp reversals. If we don’t see a significant surge in buying interest to confirm any upward movement, a pullback becomes more likely. We need conviction from buyers to sustain a rebound.
HIMS Stock Support & Resistance: Your Trading Plan
Identifying key support and resistance levels is fundamental to any trading strategy. Here’s a quick trading plan for HIMS:
Trading Plan:
- ✅ If HIMS manages to hold above $39.19 → The bullish trend could resume, with the next target at $50.99.
- ⚠️ If HIMS breaks below $39.19 → Expect a dip towards $32.26.
- 🛑 A drop below $32.26 → This could trigger a much deeper correction, potentially heading towards the 200-day SMA at $51.34.
HIMS Stock: Buy, Hold, or Sell? Our Technical Verdict
Based on our technical analysis, here’s what we’re seeing for different types of investors:
- Short-Term Traders: The trend currently appears positive, but it’s essential to monitor for any signs of exhaustion. A neutral stance might be the safest approach until a clearer signal emerges from the MACD or significant volume changes.
- Long-Term Investors: The long-term uptrend for HIMS remains valid as long as the price holds above the 200-day SMA ($51.34). A pullback to the 50-day SMA ($46.65) area could present a safer, more attractive buying opportunity for those looking to build a long-term position.
- New Buyers: It’s probably best to avoid chasing the rally right now. Instead, wait for either a confirmed breakout above $50.99 with strong, convincing volume, or a pullback to the $39.19 area. This would offer a much better risk/reward entry point.
Bottom Line:
The technical indicators suggest that the recent rally for HIMS might be losing steam in the short term. While the long-term trend still looks bullish, a correction seems plausible before the stock makes its next significant move. Trade carefully, and always wait for clear confirmation at these key technical levels.
HIMS Historical Stock Performance & Trading Data
Let’s zoom in on HIMS’s recent historical performance to understand how the stock has behaved. Over the last 15 trading days, specifically from November 07, 2025, to November 21, 2025, HIMS experienced a return of -15.40%.
During this period, the stock traded within a range of $32.88 and $42.70. The average daily trading volume during this time was approximately 27,168,767 shares. This gives us a clearer picture of the stock’s recent price action and liquidity.
HIMS Recent Daily Trading Data (Table)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2025-11-21 | $33.54 | $34.99 | $32.88 | $34.71 | 18,719,500 |
| 2025-11-20 | $36.78 | $37.22 | $33.47 | $33.62 | 28,325,500 |
| 2025-11-19 | $36.60 | $36.60 | $34.43 | $35.83 | 20,963,500 |
| 2025-11-18 | $35.71 | $36.74 | $34.13 | $36.26 | 26,537,300 |
| 2025-11-17 | $36.67 | $37.63 | $33.91 | $35.58 | 30,155,500 |
| 2025-11-16 | $35.42 | $38.09 | $34.93 | $36.98 | 31,484,900 |
| 2025-11-15 | $35.42 | $38.09 | $34.93 | $36.98 | 31,484,900 |
| 2025-11-14 | $35.42 | $38.09 | $34.93 | $36.98 | 31,484,900 |
| 2025-11-13 | $38.92 | $38.96 | $35.78 | $36.05 | 34,913,200 |
| 2025-11-12 | $39.61 | $40.25 | $38.26 | $39.02 | 21,967,400 |
| 2025-11-11 | $40.91 | $41.28 | $38.87 | $39.75 | 22,892,200 |
| 2025-11-10 | $42.49 | $42.70 | $40.22 | $41.05 | 21,798,900 |
| 2025-11-09 | $40.74 | $41.28 | $39.34 | $41.03 | 28,934,600 |
| 2025-11-08 | $40.74 | $41.28 | $39.34 | $41.03 | 28,934,600 |
| 2025-11-07 | $40.74 | $41.28 | $39.34 | $41.03 | 28,934,600 |
HIMS Stock Price Statistics: Volatility & Moving Averages
When we examine HIMS’s price range over the past year, we see a high of $72.98 and a low of $23.97. This wide fluctuation clearly indicates that the stock has experienced significant volatility, likely influenced by broader market sentiment or specific company news. Currently, the 50-day moving average stands at $49.10, which is below the 200-day moving average of $46.78. This configuration might signal a period of short-term pullback or consolidation, especially for technical traders who track momentum and trend direction.
The stock carries a beta of 2.40x, meaning HIMS tends to move much more sharply than the broader market—specifically, about 140% more volatile. Coupled with a high 30-day annualized volatility of 43.4%, it’s evident that this stock experiences frequent and substantial price swings. For investors, this translates into a higher potential for gains, but also a proportionally higher downside risk. These indicators are crucial considerations when deciding on position sizing or optimizing entry timing, especially if you’re building a portfolio that aims to balance stability with growth exposure.
| Metric | Value |
|---|---|
| 52 Week High | $72.98 |
| 52 Week Low | $23.97 |
| 50 Day MA | $49.10 |
| 200 Day MA | $46.78 |
| Beta | 2.40x |
| Volatility (30d Ann.) | 43.4% |
HIMS Quarterly Earnings Performance & Growth Metrics
Let’s turn our attention to HIMS’s recent quarterly performance, which provides a fresh look at the company’s operational strength. In its latest reported quarter, HIMS posted revenues of $598.98 million and a net income of $15.77 million.
The company saw a quarter-over-quarter revenue change of +9.9%, indicating steady sequential growth. More impressively, the year-over-year revenue growth stands at a robust +49.2%, showcasing HIMS’s strong expansion trajectory.
HIMS Last Four Quarterly Results (Table)
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| 2025-Q3 | $598.98 M | $15.77 M | 0.06x | 73.8% |
| 2025-Q2 | $544.83 M | $42.51 M | 0.17x | 76.4% |
| 2025-Q1 | $586.01 M | $49.48 M | 0.20x | 73.5% |
| 2024-Q4 | $481.14 M | $26.02 M | 0.11x | 76.8% |
HIMS Quarterly Growth Metrics (Table)
| Metric | Value |
|---|---|
| QoQ Revenue Growth | +9.9% |
| QoQ Net Income Growth | -62.9% |
| YoY Revenue Growth | +49.2% |
HIMS Upcoming Earnings Report Details
For investors tracking HIMS, the next earnings report is a key event to mark on your calendar. The company is scheduled to release its next report on November 04, 2025. The earnings call will also take place on the same day, November 04, 2025, at 03:30 AM ET. These dates are crucial for understanding the company’s latest financial health and future outlook.
HIMS Short Selling Insights: Bearish Bets & Short Squeeze Potential
Understanding short interest can give us a glimpse into market sentiment and potential future price movements. Currently, there are 70 million shares of HIMS held in short positions. The short ratio, also known as “days to cover,” stands at 2.5x. This means that, based on the stock’s recent average trading volume, it would take approximately 2.5 days for all short positions to be covered. This relatively low number suggests that short sellers don’t currently exert significant control over the stock’s price, and the risk of a prolonged “short squeeze” appears to be relatively low.
However, with 38.12% of the public float sold short, it’s clear that a significant portion of the market holds a bearish conviction regarding HIMS. This percentage has remained relatively stable compared to last month’s figure of 71 million shares shorted, indicating a consistent bearish sentiment. While a low days-to-cover ratio might temper short squeeze concerns, the substantial percentage of the float being shorted means investors should still be aware of potential volatility spikes. These spikes could be triggered by unexpected news events that force short sellers to quickly cover their positions.
| Metric | Value |
|---|---|
| Shares Short | 70 M |
| Short Ratio (Days To Cover) | 2.50x |
| Short % of Float | 38.12% |
| Shares Short (Prior Month) | 71 M |
| Short Date | 2025-10-31 |
HIMS Stock Risk Analysis: Volatility, VaR & Drawdown
Every investment comes with its share of risks, and for HIMS, understanding its risk profile is critical. The stock exhibits high volatility, with an annualized volatility of 62.7%. This indicates a significant level of investment risk, meaning you should be prepared for substantial price swings.
The Sharpe ratio, at 0.51x, suggests mixed risk-adjusted returns. While it considers both return and risk, it’s not signaling overwhelmingly superior performance relative to its volatility. Furthermore, the maximum drawdown of -87.29% highlights the considerable downside risk HIMS has experienced during adverse market conditions. This is a crucial figure to understand, as it represents the largest percentage drop from a peak to a trough.
The Value at Risk (VaR) at a 5% confidence level indicates a potential loss of -5.71% in the worst 5% of scenarios. This metric helps quantify potential losses over a specific time horizon. Additionally, the Sortino ratio of 0.73x specifically focuses on downside risk, providing further insight into risk-adjusted performance by only penalizing returns that fall below a specified target. Investors absolutely should consider these risk metrics in conjunction with their own risk tolerance and investment objectives.
| Metric | Value |
|---|---|
| Volatility (Annualized) | 62.7% |
| Value at Risk (5%) | -5.71% |
| Value at Risk (1%) | -9.77% |
| Sharpe Ratio | 0.51x |
| Sortino Ratio | 0.73x |
| Maximum Drawdown | -87.29% |
| Skewness | 0.63x |
| Kurtosis | 12.34x |
HIMS Stock Sentiment Analysis: News, Analysts & Options
Current market sentiment for HIMS reveals a cautiously positive outlook, driven by a composite sentiment score of 0.11x and a confidence level of 40.2%. This overall positive sentiment isn’t just a hunch; it’s derived from analyzing multiple data sources, including recent news coverage, analyst recommendations, and activity in the options market.
When we break down these sentiment components, we see that news analysis shows a Neutral sentiment (0.05x), while the analyst consensus also indicates a Neutral stance (0.00x). What’s pushing the overall sentiment into positive territory is the options market, which reflects a Positive sentiment (0.34x). This suggests that options traders are leaning bullish. While this weak overall positive signal is interesting, it should always be considered alongside a thorough fundamental and technical analysis to form a truly comprehensive investment perspective.
| Metric | Value |
|---|---|
| Composite Sentiment Score | 0.11x |
| Sentiment Classification | Positive |
| Sentiment Confidence | 40.2% |
| News Sentiment | Neutral (0.05x) |
| Analyst Sentiment | Neutral (0.00x) |
| Options Sentiment | Positive (0.34x) |
| Put/Call Ratio | 0.33x |
You May Like – Johnson & Johnson (JNJ) Stock Analysis: Comprehensive Investment Guide & Market Insights
HIMS Peer Comparison: How Hims & Hers Health Stacks Up
Comparing HIMS to its peers gives us a crucial perspective on its relative strengths and weaknesses within the industry. With a market cap of $7.90 billion, HIMS is currently the smallest player among the selected peers, trailing behind LH ($22.07B) and DGX ($21.39B).
HIMS’s elevated P/E ratio of 65.49x indicates a premium valuation, often reflecting strong growth prospects and investor optimism. In terms of growth, HIMS truly stands out with exceptional revenue growth of 49.2%, significantly outpacing its peers. While its net margin of 6.05% shows positive but modest profitability compared to LH (6.21%) and DGX (8.93%), it’s important to consider its growth stage.
What’s truly impressive is HIMS’s Return on Equity (ROE) of 26.21%, indicating highly efficient use of shareholder equity, outperforming both LH (10.14%) and DGX (14.35%). Regarding leverage, HIMS maintains a moderate debt-to-equity ratio of 192. When it comes to dividends, the policies vary; LH (1.08%) and DGX (1.67%) reward shareholders with payouts, whereas HIMS reinvests all its cash back into growth initiatives, which is typical for high-growth companies.
| Metric | HIMS | LH | DGX |
|---|---|---|---|
| Market Cap | $7.90B | $22.07B | $21.39B |
| P/E Ratio | 65.49 | 26.04 | 22.47 |
| Revenue Growth | 49.20% | 8.60% | 13.20% |
| Net Margin | 6.05% | 6.21% | 8.93% |
| EPS | 0.53 | 10.20 | 8.51 |
| ROE | 26.21% | 10.14% | 14.35% |
| Debt-to-Equity | 192 | 75.56 | 86.52 |
| Dividend Yield | 0.00% | 1.08% | 1.67% |
| 52-Week Range | $23.03 – $72.98 | $208.23 – $293.72 | $146.30 – $197.55 |
HIMS Insider Transactions: What Directors & Executives Are Doing
Insider transaction data offers a fascinating glimpse into how those closest to the company view its prospects. Over the last three months, the data for HIMS reveals a strong bearish trend, with 95 sells versus 29 buys. This totals $54.0 million in net sales, which includes 54 transactions where pricing was estimated.
When we focus specifically on discretionary open-market activity, there were 39 market sales compared to 0 market purchases. This clearly indicates that insiders are actively reducing their positions. Additionally, there were 72 option exercises, which could signal either confidence in future price appreciation (as they convert options to shares) or simply routine portfolio management.
A price analysis shows that sales generally occurred at elevated levels, averaging $55.15 across 45 priced transactions. In contrast, purchases averaged $6.37 across 19 transactions, suggesting strategic profit-taking by insiders. Recent market transactions lean heavily towards selling, with insiders continuing to reduce their exposure in the near term. The scale of this discretionary market selling should give investors pause; when those with the best internal visibility are reducing their stake, it warrants a careful evaluation of the near-term risk-reward dynamics.
| Insider Name | Type | Shares Changed | Price | Shares After | Transaction Date | Filing Date |
|---|---|---|---|---|---|---|
| Okupe Oluyemi | SELL (Exercise) | -15,572 | ~$35.58 | 158,808 | 2025-11-17 | 2025-11-19 |
| Okupe Oluyemi | SELL (Exercise) | -7,615 | ~$35.58 | 48,554 | 2025-11-17 | 2025-11-19 |
| Okupe Oluyemi | SELL (Sale) | -23,187 | $36.81 | 70,232 | 2025-11-17 | 2025-11-19 |
| Okupe Oluyemi | BUY (Exercise) | +15,572 | $5.01 | 93,419 | 2025-11-17 | 2025-11-19 |
| Okupe Oluyemi | BUY (Exercise) | +7,615 | $11.53 | 77,847 | 2025-11-17 | 2025-11-19 |
| Boughton Soleil | SELL (Sale) | -2,637 | $42.53 | 155,856 | 2025-11-10 | 2025-11-12 |
| Dudum Andrew | SELL (Other) | -260,000 | ~$41.05 | 2,423 | 2025-11-10 | 2025-11-12 |
| Boughton Soleil | SELL (Sale) | -2,637 | $50.10 | 158,493 | 2025-10-27 | 2025-10-28 |
| Okupe Oluyemi | SELL (Exercise) | -3,807 | ~$49.78 | 56,169 | 2025-10-17 | 2025-10-20 |
| Okupe Oluyemi | SELL (Exercise) | -7,785 | ~$49.78 | 174,380 | 2025-10-17 | 2025-10-20 |
| Okupe Oluyemi | SELL (Sale) | -11,592 | $57.13 | 70,232 | 2025-10-17 | 2025-10-20 |
| Okupe Oluyemi | BUY (Exercise) | +3,807 | $11.53 | 81,824 | 2025-10-17 | 2025-10-20 |
| Okupe Oluyemi | BUY (Exercise) | +7,785 | $5.01 | 78,017 | 2025-10-17 | 2025-10-20 |
| Dudum Andrew | SELL (Exercise) | -108,334 | ~$59.15 | 431,395 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Exercise) | -17,001 | ~$59.15 | 17,005 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -16,667 | $62.70 | 92,523 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -2,335 | $63.39 | 109,190 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -39,332 | $62.70 | 111,525 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -10,469 | $63.49 | 150,857 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -39,531 | $62.71 | 161,326 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | BUY (Exercise) | +108,334 | $2.43 | 200,857 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -17,001 | $62.69 | 92,523 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | BUY (Exercise) | +17,001 | $2.43 | 109,524 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -8,423 | $63.46 | 47,524 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -39,111 | $62.70 | 55,947 | 2025-10-16 | 2025-10-20 |
| Dudum Andrew | SELL (Sale) | -2,792 | $62.65 | 92,523 | 2025-10-16 | 2025-10-20 |
| Boughton Soleil | SELL (Sale) | -2,637 | $54.38 | 161,130 | 2025-10-13 | 2025-10-14 |
| Chi Michael | SELL (Exercise) | -900 | ~$53.95 | 115,362 | 2025-10-10 | 2025-10-14 |
| Chi Michael | SELL (Sale) | -900 | $58.25 | 291,439 | 2025-10-10 | 2025-10-14 |
| Chi Michael | BUY (Exercise) | +900 | $6.82 | 292,339 | 2025-10-10 | 2025-10-14 |
| Okupe Oluyemi | SELL (Exercise) | -3,808 | ~$52.54 | 59,976 | 2025-10-03 | 2025-10-07 |
| Okupe Oluyemi | SELL (Exercise) | -7,787 | ~$52.54 | 182,165 | 2025-10-03 | 2025-10-07 |
| Okupe Oluyemi | SELL (Sale) | -11,595 | $57.72 | 70,232 | 2025-10-03 | 2025-10-07 |
| Okupe Oluyemi | BUY (Exercise) | +3,808 | $11.53 | 81,827 | 2025-10-03 | 2025-10-07 |
| Okupe Oluyemi | BUY (Exercise) | +7,787 | $5.01 | 78,019 | 2025-10-03 | 2025-10-07 |
| Chi Michael | SELL (Exercise) | -250 | ~$56.31 | 47,106 | 2025-10-01 | 2025-10-02 |
| Chi Michael | SELL (Sale) | -250 | $56.00 | 291,439 | 2025-10-01 | 2025-10-02 |
| Chi Michael | BUY (Exercise) | +250 | $11.53 | 291,689 | 2025-10-01 | 2025-10-02 |
| Okupe Oluyemi | SELL (Exercise) | -49,832 | ~$59.12 | 189,952 | 2025-09-29 | 2025-09-30 |
| Okupe Oluyemi | SELL (Sale) | -85,000 | $60.20 | 70,232 | 2025-09-29 | 2025-09-30 |
| Okupe Oluyemi | BUY (Exercise) | +49,832 | $5.01 | 155,232 | 2025-09-29 | 2025-09-30 |
| Boughton Soleil | SELL (Sale) | -2,637 | $58.79 | 163,767 | 2025-09-29 | 2025-09-30 |
| Chi Michael | SELL (Exercise) | -2,100 | ~$53.25 | 174,042 | 2025-09-24 | 2025-09-25 |
| Chi Michael | SELL (Sale) | -2,100 | $56.52 | 291,439 | 2025-09-24 | 2025-09-25 |
| Chi Michael | BUY (Exercise) | +2,100 | $5.01 | 293,539 | 2025-09-24 | 2025-09-25 |
| Okupe Oluyemi | SELL (Sale) | -23,584 | $57.74 | 105,400 | 2025-09-22 | 2025-09-24 |
| Boughton Soleil | SELL (Sale) | -2,637 | $50.50 | 166,404 | 2025-09-17 | 2025-09-19 |
| Carroll Patrick Harrison | SELL (Sale) | -10,021 | $50.50 | 169,940 | 2025-09-17 | 2025-09-19 |
| Becklund Irene | SELL (Sale) | -8,410 | $50.50 | 1,418 | 2025-09-17 | 2025-09-19 |
| Chi Michael | SELL (Sale) | -13,749 | $50.50 | 297,139 | 2025-09-17 | 2025-09-19 |
| Dudum Andrew | SELL (Sale) | -65,110 | $50.57 | 95,315 | 2025-09-17 | 2025-09-19 |
| Dudum Andrew | SELL (Exercise) | -108,334 | ~$50.89 | 539,729 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Exercise) | -17,001 | ~$50.89 | 34,006 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -17,810 | $53.81 | 160,425 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -32,190 | $53.03 | 178,235 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -17,729 | $53.81 | 210,425 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -23,938 | $53.08 | 228,154 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -16,667 | $53.79 | 252,092 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | BUY (Exercise) | +108,334 | $2.43 | 268,759 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -17,001 | $62.69 | 92,523 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | BUY (Exercise) | +17,001 | $2.43 | 177,426 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -8,423 | $63.46 | 47,524 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -39,111 | $62.70 | 55,947 | 2025-09-16 | 2025-09-17 |
| Dudum Andrew | SELL (Sale) | -2,792 | $62.65 | 92,523 | 2025-09-16 | 2025-09-17 |
| Carroll Patrick Harrison | SELL (Exercise) | -3,533 | ~$53.96 | 49,463 | 2025-09-15 | 2025-09-17 |
| Carroll Patrick Harrison | SELL (Exercise) | -4,840 | ~$53.96 | 48,396 | 2025-09-15 | 2025-09-17 |
| Carroll Patrick Harrison | SELL (Exercise) | -8,148 | ~$53.96 | 40,744 | 2025-09-15 | 2025-09-17 |
| Carroll Patrick Harrison | SELL (Tax Payment) | -6,500 | $53.96 | 179,961 | 2025-09-15 | 2025-09-17 |
| Carroll Patrick Harrison | BUY (Exercise) | +16,521 | ~$53.96 | 186,461 | 2025-09-15 | 2025-09-17 |
| Boughton Soleil | SELL (Exercise) | -6,183 | ~$53.96 | 86,560 | 2025-09-15 | 2025-09-17 |
| Boughton Soleil | SELL (Exercise) | -12,099 | ~$53.96 | 120,990 | 2025-09-15 | 2025-09-17 |
| Boughton Soleil | SELL (Exercise) | -12,223 | ~$53.96 | 73,338 | 2025-09-15 | 2025-09-17 |
| Boughton Soleil | SELL (Exercise) | -10,915 | ~$53.96 | 21,832 | 2025-09-15 | 2025-09-17 |
| Boughton Soleil | SELL (Tax Payment) | -22,829 | $53.96 | 169,041 | 2025-09-15 | 2025-09-17 |
| Boughton Soleil | BUY (Exercise) | +41,420 | ~$53.96 | 191,870 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Exercise) | -1,392 | ~$53.96 | 19,500 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Exercise) | -4,345 | ~$53.96 | 43,449 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Exercise) | -4,065 | ~$53.96 | 24,397 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Exercise) | -2,291 | ~$53.96 | 6,873 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Exercise) | -4,019 | ~$53.96 | 8,039 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Exercise) | -1,871 | ~$53.96 | 3,743 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | SELL (Tax Payment) | -8,867 | $53.96 | 9,828 | 2025-09-15 | 2025-09-17 |
| Becklund Irene | BUY (Exercise) | +17,983 | ~$53.96 | 18,695 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -10,599 | ~$53.96 | 148,389 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -19,359 | ~$53.96 | 193,584 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -16,297 | ~$53.96 | 97,784 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -16,495 | ~$53.96 | 65,983 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -9,356 | ~$53.96 | 18,713 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -2,100 | ~$53.96 | 176,142 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -1,800 | ~$53.96 | 116,262 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Exercise) | -250 | ~$53.96 | 47,356 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Tax Payment) | -39,872 | $53.96 | 310,888 | 2025-09-15 | 2025-09-17 |
| Chi Michael | BUY (Exercise) | +72,106 | ~$53.96 | 350,760 | 2025-09-15 | 2025-09-17 |
| Chi Michael | SELL (Sale) | -4,150 | $56.00 | 278,654 | 2025-09-15 | 2025-09-17 |
| Chi Michael | BUY (Exercise) | +2,100 | $5.01 | 282,804 | 2025-09-15 | 2025-09-17 |
| Chi Michael | BUY (Exercise) | +1,800 | $6.82 | 280,704 | 2025-09-15 | 2025-09-17 |
| Chi Michael | BUY (Exercise) | +250 | $11.53 | 278,904 | 2025-09-15 | 2025-09-17 |
| Dudum Andrew | SELL (Exercise) | -19,150 | ~$53.96 | 268,106 | 2025-09-15 | 2025-09-17 |
| Dudum Andrew | SELL (Exercise) | -74,529 | ~$53.96 | 745,299 | 2025-09-15 | 2025-09-17 |
| Dudum Andrew | SELL (Exercise) | -35,447 | ~$53.96 | 212,679 | 2025-09-15 | 2025-09-17 |
| Dudum Andrew | SELL (Exercise) | -35,242 | ~$53.96 | 70,484 | 2025-09-15 | 2025-09-17 |
| Dudum Andrew | SELL (Tax Payment) | -90,672 | $53.96 | 163,217 | 2025-09-15 | 2025-09-17 |
| Dudum Andrew | BUY (Exercise) | +164,368 | ~$53.96 | 253,889 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Exercise) | -110,000 | ~$53.96 | 239,784 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Exercise) | -11,482 | ~$53.96 | 160,755 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Exercise) | -22,988 | ~$53.96 | 229,881 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Exercise) | -18,334 | ~$53.96 | 110,007 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Exercise) | -52,395 | ~$53.96 | 104,791 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Sale) | -27,208 | $55.79 | 128,984 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Sale) | -117,792 | $55.25 | 156,192 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | BUY (Exercise) | +110,000 | $5.01 | 273,984 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Tax Payment) | -58,021 | $53.96 | 163,984 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | BUY (Exercise) | +105,199 | ~$53.96 | 222,005 | 2025-09-15 | 2025-09-17 |
| Schultz Kare | SELL (Exercise) | -6,623 | ~$53.96 | 13,247 | 2025-09-15 | 2025-09-17 |
| Schultz Kare | BUY (Exercise) | +6,623 | ~$53.96 | 15,741 | 2025-09-15 | 2025-09-17 |
| Okupe Oluyemi | SELL (Exercise) | -11,581 | ~$45.35 | 349,784 | 2025-08-26 | 2025-08-28 |
| Okupe Oluyemi | SELL (Sale) | -11,581 | $43.69 | 116,806 | 2025-08-26 | 2025-08-28 |
| Okupe Oluyemi | BUY (Exercise) | +11,581 | $5.01 | 128,387 | 2025-08-26 | 2025-08-28 |
Key Risk Factors for HIMS Stock Investors
Potential investors considering HIMS should be fully aware of several inherent risk factors. This list highlights key considerations based on available data and market dynamics, but it’s important to remember that it may not encompass every possible risk.
- ⚠️ The current price of $34.71 is below the 50-Day SMA ($46.65), indicating potential short-term weakness.
- ⚠️ The price of $34.71 is also below the 200-Day SMA ($51.34), which suggests potential long-term weakness.
- ⚠️ The RSI at 23.1 is low (below 30), indicating potential oversold conditions. While this could precede a rebound, it also signals underlying weakness or could lead to further downside.
- ⚠️ HIMS has experienced negative year-over-year earnings growth of -80.30%, which raises significant concerns about its current profitability trends.
- ⚠️ General market fluctuations and broader economic conditions can significantly impact stocks in the Healthcare sector, including HIMS.
HIMS Analyst Ratings & Consensus: Price Targets & Recommendations
Let’s see what Wall Street analysts are saying about HIMS. The average recommendation among them is ‘Hold’, reflecting a cautious stance. This consensus view is based on insights from 12 analysts who have contributed their opinions.
Their price targets vary, but the average target is $46.00, with a range stretching from a low of $25.00 to a high of $85.00. Based on this mean target of $46.00, it implies a potential upside of approximately +32.5% from the current price of $34.71. This provides a snapshot of overall analyst sentiment regarding the stock’s future outlook.
| Metric | Value |
|---|---|
| Recommendation | Hold |
| Mean Target Price | $46.00 |
| High Target Price | $85.00 |
| Low Target Price | $25.00 |
| Number of Analyst Opinions | 12 |
Latest News & Developments for HIMS Stock
Staying informed about recent news and developments is crucial for any investor. These events can often act as catalysts, significantly impacting a stock’s performance. Here’s a quick look at some recent headlines concerning HIMS:
- MarketBeat Week in Review – 11/17 – 11/21 – Publisher: MarketBeat, Published: 2025-11-22T12:00:00Z
- Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model – Publisher: Zacks, Published: 2025-11-21T15:54:00Z
- OMCL or HIMS: Which Is the Better Value Stock Right Now? – Publisher: Zacks, Published: 2025-11-20T16:40:03Z
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? – Publisher: MarketBeat, Published: 2025-11-19T22:27:00Z
- Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? – Publisher: Zacks, Published: 2025-11-18T16:43:00Z
HIMS Stock: Conclusion & Investment Outlook
After a thorough analysis of HIMS, synthesizing both technical indicators and fundamental data, we can draw some informed conclusions for investors.
Short-Term Technical Outlook for HIMS
- Overall Technical Sentiment: Neutral. While there are bearish signals, some indicators suggest potential for a shift.
- Price Trend vs MAs: Bearish. The stock is currently trading below both its 50-day and 200-day moving averages.
- Momentum (RSI): Oversold (23.1). This could indicate that the stock is due for a bounce or reversal.
- Support / Resistance (30d): Key levels to watch are approximately ~$32.88 for support and ~$50.99 for resistance.
Long-Term Fundamental & Forecast Outlook for HIMS
- 1-Year Avg. Forecast: There’s a projected average change of about +74.5%, targeting approximately $60.56. This is a robust forecast.
- Fundamental Health: The assessment is incomplete, but we see a strong ROE of 26.21%, balanced by a Debt/Equity ratio of 1.92x.
- Valuation Snapshot: The stock appears elevated, with a Forward P/E of 75.46x, suggesting a premium valuation.
- Recent Growth (YoY): Mixed performance with strong revenue growth (49.20%) but negative earnings growth (-80.30%).
- Analyst Consensus: Analysts generally have a ‘Hold’ recommendation, with a mean target price of $46.00.
Overall Assessment & Outlook for HIMS Stock
Synthesizing all the data, HIMS currently presents a picture of Neutral technicals combined with moderate fundamentals. From a valuation perspective, it appears elevated, especially with a Forward P/E of 75.46x. However, looking out one year, the forecast implies a substantial potential upside of +74.5%, with an average target near $60.56. Investors should carefully weigh these diverse factors against the identified risks and align them with their individual investment horizon and risk tolerance.
Frequently Asked Questions (FAQ) About HIMS Stock
Here are some common questions investors have about HIMS stock, with answers based on our comprehensive analysis.
What is the HIMS stock price prediction for the next year (2025-2026)?
Based on current models, the average 1-year price forecast for HIMS is approximately $60.56. This represents a potential +74.5% change from the recent price of $34.71. Remember, this is a model-driven estimate, not a guarantee, and actual prices will fluctuate based on numerous market factors.
Will HIMS stock go up or down?
The 1-year forecast model suggests the price might show strong gains on average (+74.5% potential). However, the short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently ‘Neutral’), breaking news, and overall economic conditions. Technical indicators, like the stock trading below its 50-day and 200-day moving averages, provide clues for near-term direction, indicating a bearish trend, though the RSI suggests it’s oversold.
Is HIMS stock a good investment right now?
Determining if HIMS is a ‘good buy’ requires evaluating multiple factors. Technical sentiment is ‘Neutral,’ while the 1-year forecast suggests a +74.5% potential upside. Technically, the RSI indicates oversold conditions (RSI: 23.1), potentially signaling a rebound opportunity. You should consider its valuation (Forward P/E: 75.46x), strong financial health (ROE: 26.21%), and growth prospects.
However, note that 5 potentially significant risk factors specific to HIMS were identified (see Risk Factors section). Align these factors with your personal investment strategy and risk tolerance.
How volatile is HIMS stock?
Based on the recent 30-day price action, HIMS’s annualized volatility is approximately 43.4%. This level is currently considered elevated, indicating a significant degree of recent price fluctuation. This aligns with its Beta of 2.40x (see Stock Price Statistics), meaning it tends to move more sharply than the broader market. Higher volatility implies larger potential price swings, both up and down.
What is HIMS’s P/E ratio and what does it mean?
HIMS’s Trailing P/E ratio (based on past earnings) is 65.49x, which is considered relatively high, implying the market expects strong growth or potential overvaluation. The Forward P/E (based on expected earnings) is 75.46x. A P/E ratio indicates how much investors are paying per dollar of earnings. You should compare this to industry peers and historical levels. A high P/E isn’t necessarily bad if strong growth justifies it.
What are the key upcoming events for HIMS?
The next significant upcoming event for HIMS is its earnings report on November 04, 2025, with an earnings call scheduled for the same day at 03:30 AM ET. Beyond these, investors should monitor macroeconomic shifts, competitive actions within the telehealth and specialty drug market, and any major corporate announcements or strategic partnerships.
What does HIMS’s liquidity position reveal about its financial health?
HIMS’s financial health includes a strong Current Ratio of 1.88x, suggesting it can comfortably cover its short-term liabilities. Furthermore, its robust operating cash flow of $325.08 million and levered free cash flow of $195.34 million provide a significant buffer and are critical factors in its ability to fund operations, manage debt, and pursue growth initiatives.
Pingback: EVgo, Inc. (EVGO) Stock Analysis: Comprehensive Investment Guide & Market Insights - Stockdunia